Key Development
Global private equity powerhouse KKR & Co. (NYSE: KKR) has formally entered into a definitive merger agreement to acquire medical device contract development and manufacturing organization (CDMO) Integer Holdings Corporation (NYSE: ITGR). The all-cash take-private transaction values Integer at an enterprise value of approximately $5.7 billion, including the assumption of outstanding debt. The deal received unanimous approval from Integer’s Board of Directors and is expected to close before year-end 2026.
Transaction Structure & Terms:
-
Consideration: KKR will acquire all outstanding shares of Integer for $127 per share in cash. This represents a 51.8% premium over Integer’s closing share price on April 29, 2026 (prior to announcing its strategic review).
-
Listing Status: Upon deal completion, Integer will cease trading on the New York Stock Exchange (NYSE) and transition into a privately held portfolio company under KKR.
-
Guidance Update: In light of the pending acquisition, Integer has officially withdrawn its previously issued full-year 2026 financial guidance.
Why It Matters
-
Critical Node in the MedTech Supply Chain: Plano, Texas-based Integer Holdings is one of the world’s largest medical device CDMOs. The company manufactures core components and finished devices—such as cardiac leads, neuromodulation pulse generators, and electrophysiology catheters—for major medtech OEMs, including Abbott, Boston Scientific, and Medtronic.
-
KKR’s Largest Healthcare Buyout Since 2018: The transaction marks KKR’s most significant healthcare acquisition since its $9.9 billion take-private deal for Envision Healthcare in 2018. It deepens KKR’s exposure to high-growth healthcare subsectors, expanding its global footprint across its $796 billion in Assets Under Management (AUM).
-
Platform Acquisition Strategy: Financial analysts at KeyBanc Capital Markets highlight that Integer will serve as a foundational platform for KKR. Under private ownership, KKR can execute bolt-on acquisitions of smaller specialized medtech component suppliers to integrate into Integer’s operational footprint.
-
Resolving Activist Pressure: The buyout follows a period of engagement with activist investor Irenic Capital Management (which holds a >3% stake), culminating in a comprehensive board-led strategic review launched in April 2026.
Healthcare Insight Analysis
From the perspective of Healthcare Insight, KKR’s $5.7 billion buyout of Integer Holdings provides a clear example of Private Equity Capitalization of the MedTech Supply Chain.
While public equity markets have subjected medical device manufacturers to valuation volatility stemming from transient macro headwinds and supply chain cost pressures, private equity firms recognize the long-term value of mission-critical CDMO assets.
KKR is capitalizing on two major structural tailwinds:
-
Accelerating Outsourcing by MedTech OEMs: Global medical device leaders (e.g., Medtronic, Abbott, Boston Scientific) are increasingly outsourcing complex component manufacturing to specialized CDMOs like Integer. This shift allows OEMs to optimize R&D capital while securing reliable, high-purity supply chains, generating predictable long-term revenues for Integer.
-
Operational Agility Outside Public Markets: Operating as a private company provides Integer with patient, long-term capital from KKR. This enables management to expand manufacturing capacity, automate production lines, and invest in next-generation medical technologies without the friction of quarterly public earnings expectations.
This acquisition reinforces broader private equity momentum in healthcare, joining other major buyouts such as Blackstone/TPG’s $18.3 billion acquisition of Hologic and AIP’s $1.27 billion purchase of Avanos Medical.
Market Implications
-
Accelerating CDMO Industry Consolidation: Backed by KKR’s capital reserves, Integer will likely pursue aggressive M&A, acquiring niche biopharma/medtech suppliers specializing in advanced biomaterials, micro-electronics, and specialized catheter constructs.
-
Supply Chain Stability for Cardiovascular & Neuromodulation OEMs: KKR’s commitment to injecting long-term capital into Integer assures major device makers of sustained production capacity for critical cardiac rhythm management and neuromodulation components.
-
Positive Equity Market Reaction for KKR: Demonstrating disciplined capital deployment in high-quality healthcare assets drove KKR shares up by 3–5% following the transaction announcement on August 3, 2026.
Transactional Overview: KKR Acquisition of Integer Holdings
| Deal Parameter | Financial & Strategic Metrics | Strategic Rationale |
| Acquiring Sponsor | KKR & Co. Inc. (Private Equity) | Expands healthcare exposure across KKR’s $796B AUM. |
| Target Enterprise | Integer Holdings Corporation (NYSE: ITGR) | Leading global medical device CDMO. |
| Enterprise Value (EV) | ~$5.7 Billion (Includes debt assumption) | KKR’s largest healthcare transaction since 2018. |
| Cash Consideration | $127.00 Per Share (All-Cash) | Represents a 51.8% premium over pre-review trading levels. |
| Corporate Status | NYSE Delisting $\rightarrow$ Private Company | Withdraws 2026 outlook; focuses on long-term capex. |